SCHEMBL2964383

SCHEMBL2964383

Nc1cc(C(F)(F)F)ccc1-c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
KDM4E B2RXH2 2/20 0.53
MEN1 O00255 1/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
GFER P55789 1/20 0.53
KMT2A Q03164 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KIF11 P52732 1/20 0.52
HSD17B10 Q99714 2/20 0.49
HPGD P15428 2/20 0.49
PKM P14618 1/20 0.49
FEN1 P39748 1/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PTGDR2 Q9Y5Y4 2/20 0.45
GPR3 P46089 1/20 0.44
ADORA2A P29274 2/20 0.44
ADORA1 P30542 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3792211 0.85 KIF11 (0.52) ALDH1A1KDM4EMEN1GAAMAPT
SCHEMBL3788720 0.85 KIF11 (0.61) ALDH1A1KDM4EMEN1GAAMAPT
SCHEMBL3784775 0.84 TSHR (0.58) ALDH1A1KDM4EMEN1GAAMAPT
SCHEMBL6138448 0.83 ALDH1A1 (0.53) ALDH1A1KDM4EMEN1GAAMAPT
SCHEMBL671228 0.82 ALDH1A1 (0.52) ALDH1A1KDM4EMEN1GAAMAPT
SCHEMBL23198938 0.82 ALDH1A1 (0.50) ALDH1A1MEN1GAAMAPTKMT2A
SCHEMBL22636882 0.82 FEN1 (0.50) ALDH1A1KDM4EMEN1GAAMAPT
SCHEMBL28930464 0.82 RORC (0.46) ALDH1A1KDM4EMEN1MAPTKMT2A
SCHEMBL29430685 0.82 FEN1 (0.50) ALDH1A1KDM4EMEN1GAAMAPT
SCHEMBL27781322 0.82 KIF11 (0.58) ALDH1A1KIF11HPGDNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115785131-B Method for synthesizing high-efficiency luminescent complex material with tunable luminescent wavelength 五邑大学 2024-05-17 CN claimed
EP-3966196-A1 PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS Grey Wolf Therapeutics Limited (GB) 2022-03-16 EP disclosed
US-9708340-B2 Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-07-18 US disclosed
US-20160185795-A1 UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-06-30 US disclosed
US-9278918-B2 Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors HOFFMANN-LA ROCHE INC. (US) 2016-03-08 US disclosed
US-20160002152-A1 UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185795-A1 UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS FABP1, FABP5, FABP2 ALDH1A1 689/4885KDM4E 3467/4885MEN1 4879/4885
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 ALDH1A1 4339/4885KDM4E 2606/4885MEN1 174/4885
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 ALDH1A1 2723/4885KDM4E 1822/4885MEN1 4571/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 ALDH1A1 2723/4885KDM4E 1822/4885MEN1 4571/4885
US-20160002152-A1 UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS FABP1, FABP5, FABP2 ALDH1A1 689/4885KDM4E 3467/4885MEN1 4879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.